(Q35710192)

9 August 2017

1 reference

title

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials (English)

1 reference

9 August 2017

main subject

phase III clinical trial

0 references

1 reference

1 reference

Ali I Fattom

1

1 reference

9 August 2017

Gary Horwith

2

1 reference

9 August 2017

Steve Fuller

3

1 reference

9 August 2017

Myra Propst

4

1 reference

9 August 2017

Robert Naso

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

22

1 reference

9 August 2017

issue

7

1 reference

9 August 2017

page(s)

880-887

1 reference

Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Antimicrobial resistance: the example of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Speculations on the immunology of staphylococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Staphylococcal vaccines: a realistic dream

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Molecular, antibiogram and serological typing of Staphylococcus aureus isolates recovered from Al-Makased Hospital in East Jerusalem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Capsular polysaccharide serotypes of coagulase-positive staphylococci associated with tenosynovitis, osteomyelitis, and other invasive infections in chickens and turkeys: evidence for new capsular types.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Isolation of type 5 capsular polysaccharide from Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Structure of the type 5 capsular polysaccharide of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Polysaccharide-protein conjugates: a new generation of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Use of licensed vaccines for active immunization of the immunocompromised host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

7 January 2021

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

7 January 2021

Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

7 January 2021

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

7 January 2021

Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.034

7 January 2021

10.1016/J.VACCINE.2003.11.034

Identifiers

DOI

1 reference

9 August 2017

1 reference